Xiaomei Zheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Xiaomei Zheng has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Can Pang
School of Public Health, Lanzhou University, Lanzhou, China
1 shared publication - Claire Fuller
Department of Whiting School of Engineering, Johns Hopkins University, Baltimore, MD 21218, USA
1 shared publication - Hao Chi
Department of Quantitative Health Sciences, John A. Burns School of Medicine University of Hawaii at Manoa Honolulu Hawaii USA
1 shared publication - Jingwen Xiong
Department of Sports Rehabilitation, Affiliated Hospital of Southwest Medical University, Luzhou, China
1 shared publication - Ke Xu
Department of Oncology, Chongqing General Hospital, Chongqing University, Chongqing, China
1 shared publication - Lai Jiang
Clinical Medical College, Affiliated Hospital of Southwest Medical University, Luzhou, China
1 shared publication
Latest Publications
- Open Access
- 25 October 2024
- Published by Springer Nature in Discover Oncology
- Vol. 15 (1) , 1-13
The two-sided battlefield of tumour-associated macrophages in glioblastoma: unravelling their therapeutic potential
Gliomas are the most common primary malignant tumours of the central nervous system (CNS), which are highly aggressive, with increasing morbidity and mortality rates year after year, posing a serious threat to the quality and expected survival time of patients. The treatment of gliomas is a major challenge in the field of neuro-oncology, especially high-grade gliomas such as glioblastomas (GBMs). Despite considerable progress in recent years in the study of the molecular and cellular mechanisms of GBMs, their prognosis remains bleak. Tumour-associated macrophages (TAMs) account for up to 50% of GBMs, and they are a highly heterogeneous cell population whose role cannot be ignored. Here, we focus on reviewing the contribution of classically activated M1-phenotype TAMs and alternatively activated M2-phenotype TAMs to GBMs, and exploring the research progress in reprogramming M1 TAMs into M2 TAMs.
- 25 October 2024
- Published by Springer Nature in Discover Oncology
- Vol. 15 (1) , 1-13
Open AccessThe two-sided battlefield of tumour-associated macrophages in glioblastoma: unravelling their therapeutic potential
Gliomas are the most common primary malignant tumours of the central nervous system (CNS), which are highly aggressive, with increasing morbidity and mortality rates year after year, posing a serious threat to the quality and expected survival time of patients. The treatment of gliomas is a major challenge in the field of neuro-oncology, especially high-grade gliomas such as glioblastomas (GBMs). Despite considerable progress in recent years in the study of the molecular and cellular mechanisms of GBMs, their prognosis remains bleak. Tumour-associated macrophages (TAMs) account for up to 50% of GBMs, and they are a highly heterogeneous cell population whose role cannot be ignored. Here, we focus on reviewing the contribution of classically activated M1-phenotype TAMs and alternatively activated M2-phenotype TAMs to GBMs, and exploring the research progress in reprogramming M1 TAMs into M2 TAMs.